{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T10:34:22Z","timestamp":1766486062595,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s40261-021-01059-w","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T13:05:25Z","timestamp":1626872725000},"page":"733-739","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Qu\u00e9bec, Eastern Canada"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0409-0421","authenticated-orcid":false,"given":"Marzieh","family":"Eghtesadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Leroux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Pag\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"issue":"6","key":"1059_CR1","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/bcp.12591","volume":"79","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79(6):886\u201395.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1059_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s10194-019-0974-3","volume":"20","author":"TP Do","year":"2019","unstructured":"Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019;20(1):37.","journal-title":"J Headache Pain"},{"issue":"2","key":"1059_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/bmjebm-2018-110937","volume":"24","author":"P Martelletti","year":"2019","unstructured":"Martelletti P. Erenumab is effective in reducing migraine frequency and improving physical functioning. BMJ Evid-Based Med. 2019;24(2):76.","journal-title":"BMJ Evid-Based Med"},{"issue":"6","key":"1059_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40259-017-0251-4","volume":"31","author":"P Martelletti","year":"2017","unstructured":"Martelletti P. The application of CGRP(r) monoclonal antibodies in migraine spectrum: needs and priorities. BioDrugs. 2017;31(6):483\u20135.","journal-title":"BioDrugs"},{"issue":"4","key":"1059_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S2213-2600(21)00046-1","volume":"9","author":"JE Clougherty","year":"2021","unstructured":"Clougherty JE, Kinnee EJ, Cardet JC, Mauger D, Bacharier L, Beigelman A, et al. Geography, generalisability, and susceptibility in clinical trials. Lancet Respir Med. 2021;9(4):330\u20132.","journal-title":"Lancet Respir Med"},{"issue":"9453","key":"1059_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell PM. External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d Lancet. 2005;365(9453):82\u201393.","journal-title":"Lancet"},{"issue":"8","key":"1059_CR7","first-page":"963","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Res. 2003;12(8):963\u201374.","journal-title":"Qual Res"},{"issue":"1","key":"1059_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"(IHS) HCCotIHS","year":"2018","unstructured":"(IHS) HCCotIHS. The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211.","journal-title":"Cephalalgia"},{"key":"1059_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1477-7525-1-29","volume":"1","author":"RP Snaith","year":"2003","unstructured":"Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes. 2003;1:29.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"1059_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/da.10113","volume":"18","author":"KM Connor","year":"2003","unstructured":"Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety. 2003;18(2):76\u201382.","journal-title":"Depress Anxiety"},{"key":"1059_CR11","unstructured":"Aimovig\u00ae (erenumab injection) Product Monograph including patient information. https:\/\/health-products.canada.ca\/dpd-bdpp\/info.do?lang=en&code=97027. Accessed 21 Jun 2021."},{"issue":"1","key":"1059_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM, et al. European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020;21(1):76.","journal-title":"J Headache Pain"},{"issue":"10","key":"1059_CR13","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/art.1780391004","volume":"39","author":"RM Bennett","year":"1996","unstructured":"Bennett RM. Fibromyalgia and the disability dilemma. A new era in understanding a complex, multidimensional pain syndrome. Arthritis Rheum. 1996;39(10):1627\u201334.","journal-title":"Arthritis Rheum"},{"issue":"10161","key":"1059_CR14","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280\u20137.","journal-title":"Lancet"},{"issue":"10","key":"1059_CR15","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/0333102418788347","volume":"38","author":"M Ashina","year":"2018","unstructured":"Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;38(10):1611\u201321.","journal-title":"Cephalalgia"},{"issue":"1","key":"1059_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-019-1054-4","volume":"20","author":"R Ornello","year":"2019","unstructured":"Ornello R, Tiseo C, Frattale I, Perrotta G, Marini C, Pistoia F, et al. The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain. 2019;20(1):99.","journal-title":"J Headache Pain"},{"issue":"1","key":"1059_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","volume":"21","author":"A Scheffler","year":"2020","unstructured":"Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, et al. Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain. 2020;21(1):84.","journal-title":"J Headache Pain"},{"issue":"1","key":"1059_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","volume":"22","author":"I Frattale","year":"2021","unstructured":"Frattale I, Caponnetto V, Casalena A, Assetta M, Maddestra M, Marzoli F, et al. Association between response to triptans and response to erenumab: real-life data. J Headache Pain. 2021;22(1):1.","journal-title":"J Headache Pain"},{"issue":"10","key":"1059_CR19","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/head.13968","volume":"60","author":"S Cheng","year":"2020","unstructured":"Cheng S, Jenkins B, Limberg N, Hutton E. Erenumab in chronic migraine: an Australian experience. Headache. 2020;60(10):2555\u201362.","journal-title":"Headache"},{"issue":"13","key":"1059_CR20","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"40","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, Hettie G, Loder E, Burch R. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia. 2020;40(13):1511\u20131522. https:\/\/doi.org\/10.1177\/0333102420946725","journal-title":"Cephalalgia"},{"issue":"4","key":"1059_CR21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/head.14096","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Cheng S, Numachi Y, et al. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine. Headache. 2021;61(4):653\u201361.","journal-title":"Headache"},{"issue":"1","key":"1059_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):32.","journal-title":"J Headache Pain"},{"issue":"1","key":"1059_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S, et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 2020;21(1):69.","journal-title":"J Headache Pain"},{"issue":"1","key":"1059_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020;21(1):61.","journal-title":"J Headache Pain"},{"key":"1059_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fneur.2020.00417","volume":"11","author":"B Raffaelli","year":"2020","unstructured":"Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A, et al. Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxina: a dual-center retrospective observational study. Front Neurol. 2020;11:417.","journal-title":"Front Neurol"},{"issue":"9","key":"1059_CR26","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache. 2020;60(9):2014\u201325.","journal-title":"Headache"},{"issue":"4","key":"1059_CR27","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/head.14068","volume":"61","author":"DM Hines","year":"2021","unstructured":"Hines DM, Shah S, Multani JK, Wade RL, Buse DC, Bensink M. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States. Headache. 2021;61(4):590\u2013602.","journal-title":"Headache"},{"issue":"6","key":"1059_CR28","first-page":"58","volume":"19","author":"L Robbins","year":"2019","unstructured":"Robbins L. CGRP monoclonal antibodies for chronic migraine: year 1 of clinical use. Pract Pain Manag. 2019;19(6):58\u201362.","journal-title":"Pract Pain Manag"},{"issue":"1","key":"1059_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1526-4610.2011.02050.x","volume":"52","author":"DC Buse","year":"2012","unstructured":"Buse DC, Pearlman SH, Reed ML, Serrano D, Ng-Mak DS, Lipton RB. Opioid use and dependence among persons with migraine: results of the AMPP study. Headache. 2012;52(1):18\u201336.","journal-title":"Headache"},{"issue":"1","key":"1059_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","volume":"19","author":"AM Blumenfeld","year":"2018","unstructured":"Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack AA. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13.","journal-title":"J Headache Pain"},{"issue":"1","key":"1059_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s10194-018-0953-0","volume":"20","author":"WB Young","year":"2019","unstructured":"Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, et al. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study. J Headache Pain. 2019;20(1):12.","journal-title":"J Headache Pain"},{"issue":"10","key":"1059_CR32","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s10072-017-3054-y","volume":"38","author":"A Santoro","year":"2017","unstructured":"Santoro A, Fontana A, Miscio AM, Zarrelli MM, Copetti M, Leone MA. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting. Neurol Sci. 2017;38(10):1779\u201389.","journal-title":"Neurol Sci"},{"issue":"5","key":"1059_CR33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40263-014-0156-4","volume":"28","author":"ME Bigal","year":"2014","unstructured":"Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014;28(5):389\u201399.","journal-title":"CNS Drugs"},{"issue":"11","key":"1059_CR34","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/S1474-4422(14)70209-1","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100\u20137.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1059_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/bcp.12618","volume":"80","author":"L Edvinsson","year":"2015","unstructured":"Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015;80(2):193\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"46","key":"1059_CR36","doi-asserted-by":"publisher","first-page":"18985","DOI":"10.1073\/pnas.1215435109","volume":"109","author":"A Tozzi","year":"2012","unstructured":"Tozzi A, de Iure A, Di Filippo M, Costa C, Caproni S, Pisani A, et al. Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci USA. 2012;109(46):18985\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"1059_CR37","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1111\/head.13855","volume":"60","author":"E Kearney","year":"2020","unstructured":"Kearney E, Collins T, Sengupta S. De novo visual aura onset in a migraineur on Galcanezumab-Gnlm. Headache. 2020;60(7):1435\u20137.","journal-title":"Headache"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01059-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01059-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01059-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T04:07:21Z","timestamp":1628568441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01059-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1059"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01059-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"5 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not funded\u00a0was used to conduct this study. GP is a research scholar from the Fonds de recherche du Qu\u00e9bec\u2013sant\u00e9.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"ME reports personal fees from Novartis, Lilly Canada, TEVA Neurosciences, and\u00a0Aralez, outside the submitted work. EL reports personal fees from Allergan, TEVA Neurosciences, Novartis, Aralez, Lilly Canada, Lundbeck, McKesson, and\u00a0Medscape, outside the submitted work. GP reports no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of the Montreal University Health Center. As this was a retrospective study, with fully anonymized data collection obtained during standard patient care, written informed consent was waived by the Institutional Review Board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are not publicly available in accordance with ethics approval given by the ethics board from the participating university. Interested investigators may submit inquiries to the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ME, EL and GP made substantial contributions to the analysis or interpretation of data, drafted the work, substantively revised it, approved the final submission, and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}